Literature DB >> 1315781

Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study.

S C Henzen-Logmans1, M E van der Burg, J A Foekens, P M Berns, R Brussée, J H Fieret, J G Klijn, S Chadha, C J Rodenburg.   

Abstract

Epidermal growth factor receptor (EGF-R) was studied with monoclonal antibody 2E9 on 50 ovarian tumors of various histological types and 10 non-tumorous ovarian tissues by immunohistochemistry. Enhanced expression was observed in 26/50 (52%) of the tumors. Only 25 out of 46 epithelial tumors (54%) showed positivity in epithelial tumor cells. Staining was cytoplasmic in all cases. No correlation was established between EGF-R expression and the histological type of the epithelial tumor. Apart from EGF-R expression in tumor cells, low immunoreactivity was also observed in stromal and endothelial cells in both normal and tumorous ovarian tissues. Furthermore in 8/9 specimens containing necrotic areas, EGF-R was noticed in these areas as well. Both of the latter observations may have impact on the evaluation of the prognostic value of EGF-R activity in tumors, when based on EGF-R measurements using biochemical binding studies. We therefore recommend that EGF-R is measured with both methods in studies regarding its clinical value.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315781     DOI: 10.1007/bf01208620

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma.

Authors:  W Yasui; J Hata; H Yokozaki; H Nakatani; A Ochiai; H Ito; E Tahara
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

2.  Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.

Authors:  G P Sutton; F B Stehman; L H Einhorn; L M Roth; J A Blessing; C E Ehrlich
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

3.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor.

Authors:  A B Schreiber; M E Winkler; R Derynck
Journal:  Science       Date:  1986-06-06       Impact factor: 47.728

Review 4.  Antireceptor antibodies in the study of EGF-receptor interaction.

Authors:  L H Defize; C L Mummery; W H Moolenaar; S W de Laat
Journal:  Cell Differ       Date:  1987-03

5.  Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

Authors:  J A Foekens; H Portengen; W L van Putten; A M Trapman; J C Reubi; J Alexieva-Figusch; J G Klijn
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

6.  Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition.

Authors:  M R Green; J R Couchman
Journal:  J Invest Dermatol       Date:  1985-09       Impact factor: 8.551

7.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

8.  Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method.

Authors:  A Nonomura; G Ohta; Y Nakanuma; R Izumi; Y Mizukami; F Matsubara; M Hayashi; K Watanabe; N Takayanagi
Journal:  Liver       Date:  1988-06

9.  Diminished in vitro tyrosine kinase activity of the EGF receptor of senescent human fibroblasts.

Authors:  C R Carlin; P D Phillips; B B Knowles; V J Cristofalo
Journal:  Nature       Date:  1983 Dec 8-14       Impact factor: 49.962

10.  Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors.

Authors:  L H Defize; J Boonstra; J Meisenhelder; W Kruijer; L G Tertoolen; B C Tilly; T Hunter; P M van Bergen en Henegouwen; W H Moolenaar; S W de Laat
Journal:  J Cell Biol       Date:  1989-11       Impact factor: 10.539

View more
  4 in total

1.  Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.

Authors:  Sofia Levva; Vassiliki Kotoula; Ioannis Kostopoulos; Kyriaki Manousou; Christos Papadimitriou; Kyriaki Papadopoulou; Sotiris Lakis; Kyriakos Koukoulias; Vasilios Karavasilis; George Pentheroudakis; Eufemia Balassi; Flora Zagouri; Ioannis G Kaklamanos; Dimitrios Pectasides; Evangelia Razis; Gerasimos Aravantinos; Pavlos Papakostas; Dimitrios Bafaloukos; Grigorios Rallis; Helen Gogas; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

2.  Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

Authors:  Ben-Fillippo Krippendorff; Diego A Oyarzún; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-08       Impact factor: 2.745

3.  Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen.

Authors:  Natalie M Moss; Yueying Liu; Jeff J Johnson; Philip Debiase; Jonathan Jones; Laurie G Hudson; Hidayatullah G Munshi; M Sharon Stack
Journal:  Mol Cancer Res       Date:  2009-06-09       Impact factor: 5.852

4.  EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.

Authors:  Christine Mehner; Ann L Oberg; Krista M Goergen; Kimberly R Kalli; Matthew J Maurer; Aziza Nassar; Ellen L Goode; Gary L Keeney; Aminah Jatoi; Derek C Radisky; Evette S Radisky
Journal:  Genes Cancer       Date:  2017-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.